It can inhibit EGFR expression by affecting the 3′-UTR activity of EGFR mRNA [86], and block the cell cycle by acting on cyclin-dependent kinases 4 (CDK4) [87], thereby inhibiting tumor progression. This evidence concerns the gene EGFR and neoplasm.